— Stellarex is the only low-dose [1] drug-coated balloon (DCB) to demonstrate a significant treatment effect and high safety profile through 3 years — ILLUMENATE Pivotal trial showcases durable primary patency (maintained blood flow) in the most complex patient pool studied in a DCB randomized clinical trial — No significant difference in mortality compared to standard of care through three years
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.